Previous 10 | Next 10 |
Warren Buffett's Berkshire Hathaway (NYSE:BRK.B) (NYSE:BRK.A) took new stakes in Activision Blizzard (NASDAQ:ATVI) at 14.7M shares and in Nu Holdings (NYSE:NU) at 107M shares during the last quarter of 2021, according to its latest 13F filing. The investment firm divested its stake in pharmac...
Royalty Pharma (NASDAQ:RPRX) is scheduled to announce Q4 earnings results on Tuesday, February 15th, before market open. The consensus EPS Estimate is $0.78 and the consensus Revenue Estimate is $543.37M (compared to $572M in year ago quarter). Over the last 3 months, EPS estimates have seen ...
ABG,ACRE,OTCQX:ALEAF,ALLE,ALLT,ARCH,ASC,BKI,BWA,CCRD,CEVA,ECL,OTCPK:ENGIY,ESEA,FIS,OTCQB:FNMA,GILT,OTCPK:GLCNF,HSIC,HUN,IPGP,IQV,KRNT,LDOS,LGIH,MAR,NXRT,PTN,QSR,RPRX,SABR,SAFE,TRP,TRTN,USAC,OTCQX:VYGVF,WCC,YNDX,ZTS For Seeking Alpha's full earnings season calendar, click here. For furt...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million from their flagship product Orladeyo in FY2021 and raised guidance to a minimum of $250 million for FY2022. BioCryst has started e...
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15, 2022 before the U.S. financial markets open. The company will host a conference call and simulta...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chamath Palihapitiya’s Social Capital Suvretta Holdings III (NASDAQ: DNAC ) announced this morning it is merging with medical technology company ProKidney in a $2.6 billion deal. This move seems to have inves...
2021 Net cash provided by operating activities (GAAP) expected to be in the range of $2,010 to $2,030 million; 2021 Adjusted Cash Receipts (non-GAAP) expected to be at high end of guidance range of $2,110 to $2,130 million 20 therapies added to portfolio in 2020-2021; 9 are cu...
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30...
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30 a...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...